MeSH term
Frequency | Condition_Probility | Biological Markers/analysis | 3 | 0.0 |
Humans | 104 | 0.0 |
Immunohistochemistry | 28 | 0.0 |
Rhabdomyosarcoma/*metabolism/pathology | 3 | 50.0 |
Child, Preschool | 14 | 0.0 |
Comparative Study | 12 | 0.0 |
Female | 36 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Adult | 32 | 0.0 |
Animals | 37 | 0.0 |
Base Sequence | 21 | 0.0 |
Blotting, Southern | 9 | 0.0 |
Child | 16 | 0.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Infant | 10 | 0.0 |
Mice | 22 | 0.0 |
Mice, Nude | 2 | 0.0 |
Molecular Sequence Data | 24 | 0.0 |
Research Support, Non-U.S. Gov't | 55 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
*DNA Methylation | 11 | 1.0 |
DNA Primers | 3 | 0.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Genetic Markers | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 32 | 0.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Actins/analysis | 5 | 2.0 |
Aged | 14 | 0.0 |
Diagnosis, Differential | 14 | 0.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Myoglobin/analysis | 5 | 50.0 |
Myosins/analysis | 6 | 37.0 |
Prognosis | 7 | 0.0 |
Adolescent | 21 | 0.0 |
Azacitidine/*analogs & derivatives/pharmacology | 3 | 4.0 |
Male | 35 | 0.0 |
Middle Aged | 24 | 0.0 |
Neoplasm Proteins/*metabolism | 3 | 0.0 |
Promoter Regions (Genetics) | 10 | 0.0 |
Cells, Cultured | 9 | 0.0 |
Culture Media | 2 | 0.0 |
*Muscle Development | 3 | 21.0 |
MyoD Protein/analysis | 6 | 100.0 |
Gene Expression | 6 | 0.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
MyoD Protein/*metabolism | 4 | 30.0 |
Soft Tissue Neoplasms/*metabolism/pathology | 2 | 16.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Desmin/analysis | 6 | 9.0 |
Microscopy, Electron | 10 | 0.0 |
Cattle/*genetics | 2 | 1.0 |
Chromosome Banding | 3 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Muscle, Skeletal/chemistry | 2 | 10.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Translocation, Genetic | 4 | 0.0 |
Neoplasm Proteins/analysis | 3 | 0.0 |
Tumor Markers, Biological/analysis | 4 | 0.0 |
*Chromosomes, Human, Pair 11 | 5 | 0.0 |
Gestational Age | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
MyoD Protein/*genetics | 6 | 54.0 |
Tumor Markers, Biological/genetics/*metabolism | 2 | 5.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Actins/genetics | 2 | 1.0 |
Muscle Proteins/genetics | 8 | 11.0 |
MyoD Protein/genetics | 4 | 28.0 |
Myogenin/genetics | 2 | 25.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Soft Tissue Neoplasms/metabolism/*pathology | 3 | 20.0 |
Blotting, Western | 3 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Phenotype | 7 | 0.0 |
Rats | 9 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Cell Division | 7 | 0.0 |
Loss of Heterozygosity | 2 | 0.0 |
Cell Differentiation | 10 | 0.0 |
Desmin/metabolism | 3 | 12.0 |
Histiocytoma, Fibrous/metabolism/*pathology | 2 | 22.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
MyoD Protein/*analysis | 3 | 100.0 |
Myogenin/*analysis | 2 | 100.0 |
MyoD Protein/*analysis/immunology | 3 | 100.0 |
Myogenin/*analysis/immunology | 2 | 100.0 |
Fatal Outcome | 3 | 0.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Actins/metabolism | 2 | 0.0 |
MyoD Protein/metabolism | 2 | 10.0 |
Myogenin/metabolism | 2 | 28.0 |
Desmin/*analysis/immunology | 2 | 100.0 |
Cloning, Molecular | 8 | 0.0 |
Trans-Activators/genetics | 2 | 0.0 |
English Abstract | 3 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
Mutation | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
*DNA-Binding Proteins | 7 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
*Trans-Activators | 5 | 0.0 |
Rhabdomyosarcoma, Alveolar/*diagnosis/pathology | 2 | 100.0 |
Rhabdomyosarcoma/*metabolism | 2 | 28.0 |
Blotting, Northern | 8 | 0.0 |
Amino Acid Sequence | 14 | 0.0 |
Binding Sites | 3 | 0.0 |
*Genes, Structural | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
*Helix-Loop-Helix Motifs | 2 | 2.0 |
Time Factors | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Signal Transduction | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
*Multigene Family | 3 | 0.0 |
Restriction Mapping | 5 | 0.0 |
Calcitonin/genetics | 2 | 28.0 |
DNA/metabolism | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Staining and Labeling | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
3T3 Cells | 2 | 0.0 |
DNA | 3 | 0.0 |
*Gene Expression Regulation | 5 | 0.0 |
Muscles/*metabolism | 4 | 5.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Clone Cells | 2 | 0.0 |
Chick Embryo | 2 | 0.0 |
*Gene Expression | 3 | 0.0 |
*MyoD Protein | 11 | 84.0 |
Myogenin | 9 | 64.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Cell Line | 13 | 0.0 |
*Enhancer Elements (Genetics) | 3 | 1.0 |
Muscle Proteins/metabolism | 2 | 4.0 |
MyoD Protein | 4 | 44.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Transcription Factors | 2 | 2.0 |
Transfection | 6 | 0.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
*Genes, Regulator | 5 | 4.0 |
Muscles/*embryology | 2 | 40.0 |
In Vitro | 2 | 0.0 |
Mesoderm/*cytology/metabolism | 2 | 28.0 |
*Chromosome Aberrations | 2 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Genes, Structural | 3 | 0.0 |
RNA, Neoplasm/genetics | 3 | 0.0 |
DNA/genetics | 5 | 0.0 |
Muscle Proteins/*genetics | 4 | 2.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Nuclear Proteins/*genetics | 3 | 0.0 |
Phosphoproteins/*genetics | 3 | 1.0 |
*CpG Islands | 2 | 2.0 |
Blood | 2 | 1.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Actins/biosynthesis | 2 | 4.0 |
DNA Probes | 2 | 0.0 |
*Myogenic Regulatory Factors | 2 | 40.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Muscles/*cytology | 3 | 11.0 |
Genotype | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics | 2 | 1.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Proto-Oncogene Proteins c-myc | 2 | 5.0 |
Brain/pathology | 2 | 0.0 |
Muscle, Smooth/metabolism | 2 | 3.0 |
